KIT and gastrointestinal stromal tumor: And the second-and third-line therapies for GIST patients consist of sunitinib malate (Sutent) and regorafenib (Stivarga), which are TKIs with activities against KIT, PDGFR and other targets like Raf-1 proto-oncogene serine/threonine kinase (RAF1), v-raf murine viral oncogene homolog B1 (BRAF) and fibroblast growth factor (FGFR) (Rock et al., 2007; Demetri et al., 2009; Demetri et al., 2013).